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and ticagrelor. The concomitant use of edoxaban and antiplatelet 
agents exerted the combination effects. These results suggest that 
edoxaban alone and in combination therapies with edoxaban plus 
aspirin and edoxaban plus clopidogrel are promising options for pre-
vention of stent thrombosis. 
PB 1234 | Dental Extractions on NOACs 
withouTStopping Therapy (DENTST) Study: 
Interim Analysis
Y. Brennan1, Y. Gu2, E.J. Favaloro3, H. Crowther1, E. Kelly4, H. 
Zoellner4, M. Schifter2, J. Curnow1
1Westmead Hospital, Department of Haematology, Sydney, Australia, 2Westmead 
Hospital, Department of Oral Medicine, Oral Pathology and Special Needs Dentistry, 
Sydney, Australia, 3Westmead Hospital, Diagnostic Haemostasis Laboratory, 
Pathology West, Sydney, Australia, 4The University of Sydney, Sydney, Australia
Background: International guidelines recommend warfarin be con-
tinued for dental extractions, as bleeding rates are not high; instead, 
discontinuation can result in venous thromboembolism (VTE). There is 
currently no published data from clinical trials to guide the manage-
ment of patients on new oral anticoagulants (NOACs) requiring dental 
intervention.
Aims: To determine the safety of performing dental extractions on 
patients taking NOACs. Secondary aims are to identify factors associ-
ated with increased bleeding risk and to determine if there is a safe 
lower limit of NOAC drug level below which dental extractions may 
be safely performed.
Methods: This is a prospective cohort study with 3 groups: patients 
on NOAC, warfarin, or no anticoagulant. The study has local ethics ap-
proval and informed consent is obtained. Participants do not withhold 
their anticoagulant. Blood tests are measured immediately prior to ex-
traction. After extraction, Surgicel is placed in the socket, the socket 
then sutured and pressure applied with gauze. The gauze is weighed 
before and after haemostasis is achieved, and blood loss estimated by 
laboratory analysis. Bleeding complications are assessed at 48 hours 
and 7 days.
Results: Recruitment commenced in February 2016 with a target 
completion of November 2018. Data from 41 participants available 
at the time of abstract submission is summarised in tables 1 and 2. 
There have been 2 episodes of clinically relevant non-major bleeding: 
both were delayed bleeding requiring unanticipated dental review in 
patients on warfarin with therapeutic INRs. The difference in weight 
of gauze appears to indicate that patients on NOACs bleed less than 
warfarin. Interim blood loss analysis suggests this is typically low and 
not clinically significant. 
T A B L E  2   Anticoagulant drug levels
Oral 
anticoagulant Warfarin Apixaban Dabigatran Rivaroxaban
Assay INR Anti-Xa Dilute 
thrombin 
time
Anti-Xa
Median drug 
level (range)
2.2 
(2.0-2.4)
136.1 ng/ml 
(37.3-238.7)
122.3 ng/ml 
(68.5-188.1)
137.0 ng/ml 
(11.0-487.0)
Conclusions: Interim results suggest that bleeding outcomes in pa-
tients on NOACs are comparable and perhaps less than patients 
on warfarin. NOAC interruption may be unnecessary for dental 
extractions. 
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Background: Adequate antithrombotic medication ideally modulates 
the function of the clotting system to a certain therapeutic window 
(TW) to minimize thrombotic recurrence while maintaining adequate 
hemostasis, i.e. prevent bleeding. For anti-vitamin K (AVK) treatment 
T A B L E  1   Patient details and outcomes
Oral anticoagulant Warfarin All NOACs Apixaban Dabigatran Rivaroxaban No anticoagulant
Patient number 6 22 12 4 6 13
Total number of teeth extracted 10 48 17 15 16 27
Total number of roots extracted 15 67 27 18 22 48
Any bleeding 3 (50%) 5 (23%) 3 (25%) 1 (25%) 1 (17%) 1 (8%)
Major bleeding episodes 0 0 0 0 0 0
Clinically relevant non-major bleeding episodes 2 (33%) 0 0 0 0 0
Minor bleeding episodes 1 (17%) 5 (23%) 3 (25%) 1 (25%) 1 (17%) 1 (8%)
Difference in weight of gauze per tooth (grams) 3.24 2.00 2.91 1.80 1.29 1.82
Difference in weight of gauze per root (grams) 2.16 1.42 1.83 1.50 0.94 1.03
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the TW is roughly an international normalized ratio (INR) of 2-4. For 
heparins and direct oral anticoagulants (DOACs), the TW is unknown. 
Therefore, their dosage can only be based on the outcome of clinical 
trials using standard dosages. 
Ample evidence exists that the thrombin generating capacity (TGC) 
of plasma, measured as the area under the thrombin generation curve 
(Endogenous Thrombin Potential, ETP) is an adequate surrogate pa-
rameter for both thrombotic- and bleeding tendency. An INR of 2-4 
corresponds to a TGC of 33-66% of the normal mean, and TGC < 30% 
is the clinical limit of a bleeding phenotype in congenital bleeding dis-
orders. We therefore assume 66%>TG>33% as a tentative TW for all 
anticoagulant treatment.
Aims: To estimate the amount of patients on DOACs within the TW.
Methods: Plasmas from 60 healthy volunteers were spiked with low 
molecular weight heparin (LMWH), unfractionated heparin (UFH) or 
DOACs at concentrations that inhibit TGC in pooled normal plasma by 
40%. In plasma of 48 patients on rivaroxaban samples were harvested 
2±0.6 h after intake. The concentration of the drug was measured 
by its inhibition of factor Xa activity and the ETP was assessed by 
Calibrated Automated Thrombinography.
Results: The individual response of normal plasmas to an IC40 
concentration of heparin and DOACs proved to be highly variable 
(Table).
T A B L E  1 
 
Normal 
plasma N
CV 
(%)
Above 
TW
Below 
TW
Spiked Plasma None 60 18.0 99 0
 UFH 60 27.8 14 9
 LMWH 50 29.0 15 10
 DOAC-IIa 40 23.9 10 6
 DOAC-Xa 40 21.5 10 5
Patient 
Samples
DOAC-Xa 22 27.0 14 9
The level of the direct anti-Xa inhibitor measured in patient samples 
had a CV of 46% and a poor correlation was found between inhibition 
of ETP and the DOAC levels (Fig. 1). 
Conclusions: Inter-individual variation of both pharmacokinetics and 
pharmacodynamics of the tested DOACs is so high that maintenance 
within the TW is only possible by personalized dosage guided by the 
effect of the drug on the TGC. 
PB 1236 | Comparing the Performance of 
Different Assays for Monitoring Dabigatran 
Plasma Concentrations in Real-practice
L. Gonçalves, M. Carvalho, V. Cunha, C. Monteiro, C. Koch
Centro Hospitalar São João, Centre of Thrombosis and Hemostasis, Porto, Portugal
Background: Patients under therapeutic doses of dabigatran, a direct 
thrombin inhibitor, do not require routine coagulation monitoring. 
However, it may be important in certain clinical situations to assess an-
ticoagulant activity. Most guidelines recommend to perform activated 
partial thromboplastin time (APTT) and thrombin time as screening 
assays, and dilute thrombin time (dTT) or ecarin chromogenic assays 
(ECA) to determine dabigatran plasma concentration.
Aims: Compare the results obtained with ECA, used in our laboratory, 
and two dTT assays, and correlate ECA with APTT. This will enable us 
to choose the best test for our hospital.
Methods: Blood samples were collected from 18 patients taking 
therapeutic doses of dabigatran, admitted to our emergency room. 
Plasma dabigatran concentrations were determined with STA®-
ECA II (Diagnostica Stago) and compared with 2 methods of dilute 
thrombin time: Hemoclot® Thrombin Inhibitor (Hyphen Biomed) and 
a dilute thrombin time assay based on STA®-Thrombin. APTT was 
determined with Pathromtin® SL (Siemens). All tests were performed 
on STA-R® Max coagulation analyser (Diagnostica Stago).
Results: ECA showed high correlation with dTT assays, across a 
broad range of dabigatran levels. The correlation between ECA and 
Hemoclot® was very strong (R=0,980; R2=0,960), as well as between 
ECA and dTT based on STA®-Thrombin (R=0,994; R2=0,987). Both 
dTT assays values were similar, with excellent correlation (R=0,994; 
R2=0,989). The correlation between ECA and APPT was strong 
(R=0,814; R2=0,663). ECA showed to be more sensitive and useful for 
detecting very low dabigatran levels (limit detection level: 15 ng/ml) 
than dTT assays (limit detection level: 50 ng/ml).
Conclusions: This study showed that dTT and ECA accurately identify 
a broad range of dabigatran levels. The lower limit detected by ECA 
is 15 ng/ml, which can be important for patient needing high-risk sur-
gery. Facing these results we decide to maintain ECA as the quantita-
tive test for dabigatran in our hospital. 
F I G U R E  1
